Financial Report: Bristol-Myers Squibb 3Q

Bristol-Myers Squibb 3Q

3Q Revenues: $5.5 billion (+4%)

3Q Earnings: $1.3 billion (-54%)

YTD Revenues: $15.9 billion (+4%)

YTD Earnings: $3.5 billion (-26%)

Comments: Biopharmaceutical sales were $4.8 billion (+6%). Plavix sales were $1.6 billion (+8%). Sales of Abilify were $653 million (+16%). Reyataz sales were $360 million (+5%). Sustiva Franchise revenue was $315 million (+7%). Erbitux sales were down 3% to $179 million. Sprycel sales were up 30% to $107 million. R&D expenses were $820 million in the quarter (+5%). BMS’ share of Mead Johnson’s earnings was $127 million in the quarter (-20%).